{{expand|time=2016-06-11T11:40:33+00:00}}
{{drugbox
| verifiedrevid = 456485213
| IUPAC_name = ''N''-(2,6-dichlorophenyl)-4,5-dihydro-1''H''-imidazol-2-amine
| image = Clonidine.svg
| width = 150
| image2 = Clonidine ball-and-stick model.png
<!--Clinical data-->
| tradename = Catapres, Kapvay, Nexiclon
| Drugs.com = {{drugs.com|monograph|clonidine}}
| MedlinePlus = a682243
| licence_US = Clonidine
| pregnancy_AU = B3
| pregnancy_US = C
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| routes_of_administration = 口服、硬膜外给药、静脉注射等
<!--Pharmacokinetic data-->
| bioavailability = 75-95% (oral), 60-70% (transdermal)<ref name = clinp>{{cite journal|last1=Lowenthal|first1=DT|last2=Matzek|first2=KM|last3=MacGregor|first3=TR|title=Clinical pharmacokinetics of clonidine.|journal=Clinical Pharmacokinetics|date=May 1988|volume=14|issue=5|pages=287–310|doi=10.2165/00003088-198814050-00002|pmid=3293868}}</ref>
| protein_bound = 20-40%<ref name = MSR/>
| metabolism = [[Hepatic|Hepatic]] to inactive [[metabolite|metabolite]]s,<ref name = MSR/> 2/3 [[CYP2D6|CYP2D6]] [http://www.ncbi.nlm.nih.gov/pubmed/20570945]
| elimination_half-life = IR: 12-16 hours,<ref>{{Cite web |url=http://www.rxlist.com/kapvay-drug/clinical-pharmacology.htm |title=存档副本 |accessdate=2016-06-11 |archive-date=2017-10-12 |archive-url=https://web.archive.org/web/20171012000817/https://www.ncbi.nlm.nih.gov/pubmed/20570945 |dead-url=no }}</ref> 14 hours for repeated dosing<ref name = clinp/>
| excretion = 尿液 (72%)<ref name = MSR/>
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 4205-90-7
| ATC_prefix = C02
| ATC_suffix = AC01
| ATC_supplemental =  {{ATC|N02|CX02}}, {{ATC|S01|EA04}}
| PubChem = 2803
| IUPHAR_ligand = 516
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00575
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2701
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = MN3L5RMN02
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00281
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 3757
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 134
<!--Chemical data-->
| C=9 | H=9 | Cl=2 | N=3
| molecular_weight = 230.093 g/mol
| smiles = Clc1c(c(Cl)ccc1)N/C2=N/CCN2
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = GJSURZIOUXUGAL-UHFFFAOYSA-N
}}

'''可乐定'''（{{lang-en|'''Clonidine'''}}）（商品名稱包括'''Catapres'''、'''Kapvay'''、'''Nexiclon'''、'''Clophelin'''等）'''，是一种用来治疗[[高血压|高血压]]、[[注意力缺陷多动障碍|注意力缺陷多动障碍]]、[[焦虑症|焦虑症]]、[[抽動綜合症|抽動綜合症]]、[[偏头痛|偏头痛]]、「[[酒精|酒精]]、[[鴉片|鴉片]]、[[尼古丁|尼古丁]]的[[戒斷症狀|戒斷症狀]]」、[[潮熱|更年期潮熱]]、[[腹泻|腹泻]]和特定类型疼痛的药物。可乐定歸類為{{tsl|en|alpha-2 adrenergic receptor||α<sub>2</sub>}}{{tsl|en|adrenergic receptor agonist|腎上腺受體活化劑}}和{{tsl|en|imidazoline receptor|imidazoline受體}}活化劑，被应用于临床已有超过40年的历史。 <ref name = MD/> <ref>{{cite journal|last1=Neil|first1=MJ|title=Clonidine: clinical pharmacology and therapeutic use in pain management.|journal=Current Clinical Pharmacology|date=November 2011|volume=6|issue=4|pages=280–7|doi=10.2174/157488411798375886|pmid=21827389}}</ref>

<!--'''Clonidine''' (trade names '''Catapres''', '''Kapvay''', '''Nexiclon''', '''Clophelin''', and others) is a  medication used to treat [[hypertension|high blood pressure]], [[attention_deficit_hyperactivity_disorder|attention deficit hyperactivity disorder]], [[anxiety_disorder|anxiety disorder]]s, [[tic_disorder|tic disorder]]s, withdrawal (from either [[Alcohol_withdrawal_syndrome|alcohol]], [[Opioid_withdrawal|opioids]], or [[Nicotine_withdrawal|smoking]]), [[migraine|migraine]], [[menopause|menopausal flushing]], [[diarrhea|diarrhea]], and certain pain conditions.<ref name = MD/> It is classified as a centrally acting [[alpha-2_adrenergic_receptor|α<sub>2</sub>]] [[adrenergic_agonist|adrenergic agonist]] and [[imidazoline_receptor|imidazoline receptor]] agonist that has been in clinical use for over 40 years.<ref>{{cite journal|last1=Neil|first1=MJ|title=Clonidine: clinical pharmacology and therapeutic use in pain management.|journal=Current Clinical Pharmacology|date=November 2011|volume=6|issue=4|pages=280–7|doi=10.2174/157488411798375886|pmid=21827389}}</ref>-->

==引用==
{{reflist| 30 em | refs=

<ref name="MSR">{{cite web|title=clonidine (Rx) - Catapres, Catapres-TTS, more..|work=Medscape Reference|publisher=WebMD|accessdate=10 November 2013|url=http://reference.medscape.com/drug/catapres-tts-clonidine-342382|archive-date=2020-12-04|archive-url=https://web.archive.org/web/20201204171104/https://reference.medscape.com/drug/catapres-tts-clonidine-342382|dead-url=no}}</ref><!--<ref>{{Cite web|url = http://www.medscape.com/viewarticle/730140|title = FDA Approves Extended-Release Clonidine for Pediatric ADHD|accessdate = |website = |publisher =WebMD LLC }}</ref>-->

<ref name = "MD">{{cite web|title=Clonidine|work=Martindale: The Complete Drug Reference|publisher=Pharmaceutical Press|date=13 January 2014|accessdate=28 June 2014|url=http://www.medicinescomplete.com/mc/martindale/current/ms-11308-l.htm|editor=Brayfield, A|location=London, UK|archive-date=2021-08-28|archive-url=https://web.archive.org/web/20210828041402/https://about.medicinescomplete.com/wp-content/plugins/revslider/public/assets/js/extensions/revolution.extension.layeranimation.min.js?version=5.4.5|dead-url=no}}</ref>

}}

{{Orexigenics}}
{{Hypnotics and sedatives}}
{{ADHD_pharmacotherapies}}
{{portal bar|醫學|藥理學|神經科學}}
[[Category:降压药|Category:降压药]]